GM-CSF and Dacarbazine in Metastatic Melanoma
Author Information
Author(s): Ravaud A, Delaunay M, Chevreau C, Coulon V, Debled M, Bret-Dibat C, Courbon F, Gualde N, Bui B Nguyen
Primary Institution: Institut Bergonié, Regional Cancer Center, Bordeaux, France
Hypothesis
The study aimed to evaluate the antitumoural effect of GM-CSF alone or with dacarbazine in metastatic melanoma.
Conclusion
The study found that GM-CSF alone or in combination with dacarbazine did not show any antitumoural activity and resulted in significant toxicity.
Supporting Evidence
- No objective response was obtained from the treatments.
- 19 patients experienced at least WHO grade 3 toxicity.
- All patients had fever as a side effect.
- 29 patients had a decrease in performance status.
- 23 patients reported pain.
Takeaway
The researchers tested a treatment for melanoma but found that it didn't work and caused a lot of side effects.
Methodology
Patients were randomized into two treatment arms: one receiving GM-CSF alone and the other receiving GM-CSF with dacarbazine.
Limitations
The study had a small sample size and no objective responses were observed.
Participant Demographics
All participants had visceral metastatic melanoma, with 9 having only one metastatic site.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website